BioMS Medical named Biotech Company of the Year

    - Company to receive Gold Leaf Award from BIOTECanada at BIO 2008 -

    Toronto Stock Exchange Symbol: MS

    EDMONTON, June 11 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), is pleased to announce
that it has been selected to receive the Gold Leaf Award from BIOTECanada for
"Company of the Year". BioMS Medical will be presented with this distinguished
award on June 17, 2008 at the 2008 BIO International Convention in San Diego,
    "This award recognizes the Canadian biotech company that has
distinguished itself from its peers with strong overall performance as a
company, demonstrated leadership and significant achievement," said Peter
Brenders, President and CEO of BIOTECanada. "BioMS Medical represents these
qualities and is recognized as a leader in Canadian biotech."
    "We are honored to have received this prestigious award from
BIOTECanada," said Kevin Giese, President and CEO of BioMS Medical. "In 2007
we achieved many significant milestones as we advanced our lead drug for MS,
MBP8298 (dirucotide). This award recognizes the significant efforts made by
the dedicated employees at BioMS and the great progress we've made."

    About BIOTECanada
    BIOTECanada is dedicated to the sustainable commercial development of
biotechnology innovation in Canada. It is the national industry-funded
association with over 220 members representing the broad spectrum of biotech
constituents including emerging and established companies in the health,
industrial, and agricultural sectors, as well as academic and research
institutions and other related organizations.

    About BioMS Medical Corp.
    BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis
and is being evaluated in two pivotal phase III clinical trials for secondary
progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the
United States. It additionally is being evaluated for relapsing remitting MS
patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007,
BioMS entered into a licensing and development agreement granting Eli Lilly
and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for
an $87 million upfront payment, milestone payments and escalating royalties on
sales. For further information please visit our website at

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that MBP8298 will continue to demonstrate a satisfactory safety
profile in ongoing and future clinical trials; and that BioMS Medical Corp.
will complete the respective clinical trials within the timelines communicated
in this release. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

For further information:

For further information: Tony Hesby, Ryan Giese, Corporate
Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,
E-mail:, Internet:; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:

Organization Profile

Medwell Capital Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890